These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 34074656)

  • 1.
    Adib E; Nassar AH; Akl EW; Abou Alaiwi S; Nuzzo PV; Mouhieddine TH; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Shukla SA; Gusev A; Braun DA; Choueiri TK; Kwiatkowski DJ
    Clin Cancer Res; 2021 Jul; 27(14):4025-4035. PubMed ID: 34074656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
    Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW
    Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
    Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
    Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
    Naranbhai V; Viard M; Dean M; Groha S; Braun DA; Labaki C; Shukla SA; Yuki Y; Shah P; Chin K; Wind-Rotolo M; Mu XJ; Robbins PB; Gusev A; Choueiri TK; Gulley JL; Carrington M
    Lancet Oncol; 2022 Jan; 23(1):172-184. PubMed ID: 34895481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Value of the
    Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
    Front Immunol; 2021; 12():643282. PubMed ID: 34421886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
    Scalera S; Ricciuti B; Mazzotta M; Calonaci N; Alessi JV; Cipriani L; Bon G; Messina B; Lamberti G; Di Federico A; Pecci F; Milite S; Krasniqi E; Barba M; Vici P; Vecchione A; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Buglioni S; Pescarmona E; Sharma B; Felt KD; Lindsay J; Rodig SJ; De Maria R; Caravagna G; Cappuzzo F; Ciliberto G; Awad MM; Maugeri-Saccà M
    Ann Oncol; 2023 Mar; 34(3):275-288. PubMed ID: 36526124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
    Front Immunol; 2022; 13():953721. PubMed ID: 35979371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
    Luo J; Martucci VL; Quandt Z; Groha S; Murray MH; Lovly CM; Rizvi H; Egger JV; Plodkowski AJ; Abu-Akeel M; Schulze I; Merghoub T; Cardenas E; Huntsman S; Li M; Hu D; Gubens MA; Gusev A; Aldrich MC; Hellmann MD; Ziv E
    Clin Cancer Res; 2021 Sep; 27(18):5131-5140. PubMed ID: 34244291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
    Front Immunol; 2020; 11():1620. PubMed ID: 32903763
    [No Abstract]   [Full Text] [Related]  

  • 17. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
    Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
    J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
    Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
    Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.